PRESS RELEASE published on 10/12/2023 at 12:45, 1 year 1 month ago NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET
PRESS RELEASE published on 08/21/2023 at 12:45, 1 year 3 months ago The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides
PRESS RELEASE published on 07/11/2023 at 12:45, 1 year 4 months ago Company’s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides
PRESS RELEASE published on 07/06/2023 at 12:45, 1 year 4 months ago Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs
PRESS RELEASE published on 06/29/2023 at 12:45, 1 year 4 months ago NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun
PRESS RELEASE published on 05/31/2023 at 12:40, 1 year 5 months ago NanoViricides, Inc. to Present at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET
PRESS RELEASE published on 05/16/2023 at 12:45, 1 year 6 months ago NanoViricides Has Filed its Quarterly Report - Clinical Trials of Broad-Spectrum COVID Drug About to Begin
PRESS RELEASE published on 04/25/2023 at 12:45, 1 year 6 months ago NanoViricides is Expanding its Broad-Spectrum Antiviral Program to Explore Further Antiviral Applications of its COVID Clinical Drug Ingredient
PRESS RELEASE published on 04/17/2023 at 12:45, 1 year 7 months ago NanoViricides Has Shipped Drug Products for Impending Clinical Trials of NV-CoV-2, Its COVID Drug Candidate
PRESS RELEASE published on 04/04/2023 at 13:45, 1 year 7 months ago NanoViricides Signs a License Agreement That Includes Clinical Evaluation of Its COVID-19 Drug Candidates
Published on 11/22/2024 at 23:55, 1 day 5 hours ago Boron One Announces Early Warrant Exercise Incentive Program
Published on 11/22/2024 at 23:30, 1 day 5 hours ago Electric Royalties Enters Into Definitive Agreement to Acquire 0.75% Gross Revenue Royalty on Producing Punitaqui Copper Mine in Chile
Published on 11/22/2024 at 23:05, 1 day 6 hours ago Nexa Resources Announces Closing Transaction of Pukaqaqa Project Sale to Olympic
Published on 11/22/2024 at 22:30, 1 day 6 hours ago Delaforce Energy Corp. Announces Acquisition of Bouchard Well Service Ltd.
Published on 11/22/2024 at 18:14, 1 day 11 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 17:53, 1 day 11 hours ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 1 day 12 hours ago EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/21/2024 at 06:58, 2 days 22 hours ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 3 days 9 hours ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 3 days 11 hours ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 3 days 11 hours ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
